Stockscreener 앱 받기
6.84
1.18%
0.08
시간 외 거래:
6.84
전일 마감가:
$6.76
열려 있는:
$6.69
하루 거래량:
1.19M
Relative Volume:
1.04
시가총액:
$731.77M
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-3.5077
EPS:
-1.95
순현금흐름:
$-197.47M
1주 성능:
+1.18%
1개월 성능:
-21.11%
6개월 성능:
-54.64%
1년 성능:
-53.94%
1일 변동 폭
$6.63
$6.88
1주일 범위
$6.60
$7.42
52주 변동 폭
$6.41
$18.07
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.84 | 731.77M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
BofA Adjusts Price Target on Day One Biopharmaceuticals to $21 From $24, Keeps Buy Rating - MarketScreener
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Sold by Corebridge Financial Inc. - Defense World
Vanguard Group Inc. Lowers Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity - Seeking Alpha
Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple - MSN
KLP Kapitalforvaltning AS Invests $150,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
10 Stocks Under $10 that Will Triple - Insider Monkey
HC Wainwright Analysts Decrease Earnings Estimates for DAWN - Defense World
HC Wainwright Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
H.C. Wainwright maintains Buy on Day One Biopharmaceuticals By Investing.com - Investing.com Canada
Teacher Retirement System of Texas Buys 3,086 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Recommendation of “Buy” by Analysts - The AM Reporter
(DAWN) Investment Report - news.stocktradersdaily.com
Swiss National Bank Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Position Boosted by Bank of New York Mellon Corp - Defense World
Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential - TipRanks
Does Wolfspeed Inc (NYSE: WOLF) Still Look Hot This Week? - stocksregister.com
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rhumbline Advisers Has $957,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst Downgrade - Defense World
JPMorgan Chase & Co. Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $34.00 - Defense World
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory - Insider Monkey
Glioma Treatment Market Size Report 2034 | AnHeart Therapeutics - openPR.com
HC Wainwright Issues Positive Estimate for DAWN Earnings - MarketBeat
What is Wedbush's Forecast for DAWN Q1 Earnings? - MarketBeat
Research Analysts Offer Predictions for DAWN Q1 Earnings - Defense World
Needham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
What is Wedbush’s Forecast for DAWN Q1 Earnings? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low After Earnings Miss - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $36.00 Price Target at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Wedbush Reiterates “Outperform” Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low Following Weak Earnings - Defense World
Day One Biopharma’s Earnings Call Highlights Growth and Challenges - TipRanks
Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Profit Outlook - Simply Wall St
Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial - TipRanks
Day One Biopharmaceuticals' (DAWN) Outperform Rating Reiterated at Wedbush - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth - Investing.com Australia
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Reports Strong 2024 Results - TipRanks
Adam Dubow Sells 4,646 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock - MarketBeat
Day One Biopharmaceuticals Reports 2024 Financial Results - TipRanks
Day One Biopharmaceuticals, Inc. SEC 10-K Report - TradingView
Earnings Flash (DAWN) Day One Biopharmaceuticals Posts Q4 Revenue $131.2M, vs. FactSet Est of $27.8M - Marketscreener.com
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Day One Biopharmaceuticals Inc 주식 (DAWN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dubow Adam | GENERAL COUNSEL |
Feb 18 '25 |
Sale |
11.96 |
4,646 |
55,580 |
39,602 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Feb 18 '25 |
Sale |
11.96 |
12,048 |
144,130 |
128,015 |
2.51%
자본화:
|
볼륨(24시간):